NICE no for Roche's Avastin for breast cancer
This article was originally published in Scrip
NICE, the National Institute for health and Clinical Excellence, said in draft guidance on 9 July that it was not inclined to recommend Roche's VEGF-targeted Avastin (bevacizumab), in combination with a taxane, as a first line treatment for metastatic breast cancer for NHS patients in England and Wales.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.